A Kaplan-Meier curve is a graph that shows the proportion of a group of patients still surviving over time after a diagnosis or treatment. The line steps downward each time someone in the group dies, giving a visual picture of survival. Researchers use it to compare how long different groups live, for example under different treatments.
Origin
The method was published in 1958 by American statisticians Edward Kaplan and Paul Meier, who developed a way to estimate survival even when patients are followed for different lengths of time. It has become one of the most widely used tools in medical research.
Significance in Asbestos Context
For mesothelioma patients, Kaplan-Meier curves are how survival statistics are usually presented, whether describing the average course of the disease or the results of trials of new treatments. They show, for instance, median survival and the share of patients alive at one or two years, which can inform decisions and expectations. In litigation, these curves may appear in expert testimony about life expectancy and prognosis, which bears on damages. Reading them carefully matters, because a median figure hides a wide range and some patients live well beyond it.
Example Sentence
The oncologist showed a Kaplan-Meier curve comparing chemotherapy alone with chemotherapy plus immunotherapy, illustrating the survival benefit of adding the newer drug.
Related Terms
Median Survival, Prognosis, Survival Analysis, Clinical Trial, Life Expectancy, Epidemiology
Notes
- Ask your doctor which patient population a given curve is based on; survival differs a lot by cell type, stage, and age.
- Remember the curve shows a group average; individual outcomes vary, and median survival is not a personal deadline.
- Curves from older studies may understate today's survival, since treatments have improved; ask for recent data.
In the research library
29 studies in our medical research library mention Kaplan-Meier Curve in the title or abstract. Among the most cited:
- The IASLC Mesothelioma Staging Project: Proposals for Revisions of the N Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Pleural MesotheliomaD. Rice, K. Chansky, A. Nowak, et al, 2016 · Journal of Thoracic Oncology · cited 100 times
- Prognostic significance of the lymphocyte-to-monocyte ratio in patients with malignant pleural mesotheliomaT. Yamagishi, N. Fujimoto, H. Nishi, et al, 2015 · Lung Cancer · cited 52 times
- Deregulation of miRNAs in malignant pleural mesothelioma is associated with prognosis and suggests an alteration of cell metabolismC. De Santi, O. Melaiu, A. Bonotti, et al, 2017 · Scientific Reports · cited 47 times
- Current trends in the management of malignant peritoneal mesotheliomaJ.T. Miura, F.M. Johnston, T.C. Gamblin, et al, 2014 · Annals of Surgical Oncology · cited 37 times
- Nivolumab Plus Ipilimumab vs Nivolumab Alone in Advanced Cancers Other Than Melanoma: A Meta-AnalysisA.V. Serritella, N.K. Shenoy, 2023 · JAMA Oncology · cited 31 times
The journals that publish most on it: Translational Cancer Research (3), Urology (1), Asia-Pacific Journal of Clinical Oncology (1).
Category: Epidemiological Methods · All Lexicon terms A–Z
This page is provided for general informational purposes and does not constitute legal advice. Every asbestos case turns on its own facts, exposure history, diagnosis, deadlines, available evidence, and applicable law. Reviewing this page does not create an attorney-client relationship. For advice about your specific situation, call 833-4-ASBESTOS for a free case review.